Overview:
Secondary immunodeficiency (SID) is an impairment of the immune system that is caused by derivative factors such as diseases, medications, and environmental factors. Patients with hematologic malignancies are at risk for SID due to both their underlying disease and, oftentimes, their treatment. It is essential for health care providers caring for patients at high risk for developing SID to be aware of best diagnostic and management practices for this serious immune impairment.
In this live webcast, ancillary to the 2023 EHA Annual Meeting, international experts in SID review the pathophysiology and diagnosis in patients with hematologic malignancies and review prophylactic and management strategies, including antimicrobials, vaccinations and immunoglobulin (Ig) therapy through a series of case-based discussions. The use of Ig replacement in patients receiving CAR-T therapy will also be examined.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the clinical burden associated with SID in patients with cancer, including the importance of early and accurate diagnosis and risk stratification
- Assess pivotal clinical trial designs and data investigating current and emerging therapeutic agents, such as immunoglobulin therapy, in patients with SID
- Evaluate the clinical impact of prophylactic and therapeutic regimens on the current treatment paradigm of SID regarding infectious disease management and control
- Integrate innovative multidisciplinary tactics to effectively prevent, identify, and manage SID in patients with hematologic malignancies
Target Audience
This educational program is directed towards EHA congress attendees, including a global audience of oncologists, hematologist/oncologists, hematologists, transplantologists, and infectious disease experts involved in the diagnosis and management of patients with SID.
19:15 |
Introduction, Pre-Test, and Housekeeping Notes |
19:25 |
Burden, Pathophysiology, and Diagnosis of Secondary Immunodeficiency |
19:40 |
Approaches for Prophylaxis and Treatment of Secondary Immunodeficiencies: |
19:50 |
Medical Crossfire: Case-based Discussion |
20:20 |
Ig Replacement in Patients Receiving CAR T Cell Therapy |
20:35 |
Question & Answer Session |
20:40 |
Post-Test, Conclusions, and Key Takeaways |
20:45 |
Adjourn |
Shaji Kumar, MD
Professor of Medicine
Mayo Clinic
Maria Dimou MD, PhD
National and Kapodistrian University of Athens
Stephan Grupp, MD, PhD
Novotny Professor of Pediatrics
Children's Hospital of Philadelphia
Jose (J.C.) C. Villasboas Bisneto, MD
Mayo Clinic
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
